Venetoclax Plus Ibrutinib Combo Shows Potential in Relapsed/Refractory MCL
Andre Goy, MD, discusses the results from a small clinical trial, which was presented at the 2019 American Society of Hematology Annual Meeting that he found particularly significant for the treatment of patients with relapsed/refractory mantle cell lymphoma.
Andre Goy, MD, chief in the Division of Lymphoma, chairman and director at John Theurer (JT) Cancer Center, discusses the results from a small clinical trial, which was presented at the 2019 American Society of Hematology (ASH) Annual Meeting that he found particularly significant for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL).
Although it was a small study, Goy says the results from the combination of venetoclax (Venclexta) plus ibrutinib (Imbruvica), a biological combination, demonstrated an impressive complete response rate, as well as impressive minimal residual disease-negativity, in patients with relapsed/refractory MCL. However, what was most impressive with this combination was that some patients had to stop treatment for different reasons, but that a number of these patients remained in remission 18 months after treatment discontinuation.
It is unheard of that patients could continue to receive benefit from a biological combination after discontinuing treatment, Goy says. This demonstrates the potential to stop therapy in patients with relapsed/refractory MCL. Goy concludes that these findings may be critical in the treatment landscape of MCL.
<< View more resources and information regarding mantle cell lymphoma
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
